Split-dose or hybrid nonsteroidal anti-inflammatory drugs and N-acetylcysteine therapy for prevention of post-retrograde cholangiopancreatography pancreatitis

Table 3 Pearson’s chi-squared test comparison between the three study arms’ clinical and laboratory factors at 6 h

	Control arm	Arm 1	Arm 2	Chi-square	P
Amylasemia at 6 h				4.288	0.368
< 3 × ULN	81.6%	100.0%	85.7%
> 3 × ULN	18.4%	0.0%	14.3%
Lipasemia at 6 h				10.046	0.040
< 3 × ULN	69.4%	68.7%	71.4%
> 3 × ULN	30.6%	31.3%	28.6%
CRP at 6 h				12.165	0.058
Normal	49.0%	56.2%	57.1%
Mild increase	20.4%	12.5%	35.7%
Moderate increase	26.5%	31.2%	0.0%
Severe increase	4.1%	0.0%	7.1%
Clinico-biologic status at 6 h				0.397	0.820
PEP absent	91.8%	87.5%	92.9%
PEP	8.2%	12.5%	7.1%

Arm 1: Study group A treatment regimen;

Arm 2: Study group B treatment regimen; CRP: C-reactive peptide; ULN: Upper limit of normal; PEP: Post-endoscopic retrograde cholangiopancreatography pancreatitis.